Protagonist Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Protagonist Therapeutics's estimated annual revenue is currently $18.9M per year.
- Protagonist Therapeutics's estimated revenue per employee is $156,281
- Protagonist Therapeutics's total funding is $389M.
Employee Data
- Protagonist Therapeutics has 121 Employees.
- Protagonist Therapeutics grew their employee count by 20% last year.
Protagonist Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 14 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Protagonist Therapeutics?
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. We have successfully utilized this platform to discover PN-943 and PTG-200 which are oral, GI-restricted peptides for inflammatory bowel diseases (IBD), as well as PTG-300, an injectable peptide for rare blood disorders.
keywords:N/A
$389M
Total Funding
121
Number of Employees
$18.9M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Protagonist Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Project Manager | |
2 | Scientist | |
3 | Administrative Assistant | |
4 | Director | |
5 | Executive Assistant | |
6 | EVP, Chief Drug Discovery and Preclinical Development Officer | |
7 | President & CEO |
Protagonist Therapeutics News
The shares of Protagonist Therapeutics (NASDAQ:PTGX) have approached a 52-week low even as analysts defend the stock in reaction to the...
Shares of Protagonist Therapeutics Inc. PTGX, -0.21% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2...
Protagonist Therapeutics Inc · 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg...
NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to ...
NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Jo ...
Other Companies in Newark
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $90M | 126 | 4% | $15.9M |
#2 | $28.2M | 128 | -4% | N/A |
#3 | $26.9M | 128 | 1% | N/A |
#4 | $18.6M | 128 | 20% | N/A |
#5 | $34.6M | 128 | -4% | N/A |